1. Home
  2. GNSS vs MAIA Comparison

GNSS vs MAIA Comparison

Compare GNSS & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Genasys Inc.

GNSS

Genasys Inc.

HOLD

Current Price

$1.89

Market Cap

84.1M

ML Signal

HOLD

Logo MAIA Biotechnology Inc.

MAIA

MAIA Biotechnology Inc.

HOLD

Current Price

$1.24

Market Cap

77.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GNSS
MAIA
Founded
1992
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Consumer Electronics/Appliances
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
84.1M
77.1M
IPO Year
1996
2022

Fundamental Metrics

Financial Performance
Metric
GNSS
MAIA
Price
$1.89
$1.24
Analyst Decision
Strong Buy
Analyst Count
2
0
Target Price
$4.75
N/A
AVG Volume (30 Days)
96.8K
643.0K
Earning Date
05-12-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
44.44
33.33
EPS
N/A
N/A
Revenue
$26,306,790.00
N/A
Revenue This Year
$80.08
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
29.50
N/A
52 Week Low
$1.40
$0.87
52 Week High
$2.70
$3.19

Technical Indicators

Market Signals
Indicator
GNSS
MAIA
Relative Strength Index (RSI) 52.95 40.46
Support Level $1.87 $1.13
Resistance Level $2.05 $1.50
Average True Range (ATR) 0.08 0.10
MACD 0.00 0.01
Stochastic Oscillator 41.68 25.00

Price Performance

Historical Comparison
GNSS
MAIA

About GNSS Genasys Inc.

Genasys Inc is a provider of Protective Communication solutions, including Genasys Protect software platform and Long Range Acoustic Device (LRAD). Its software platform receives information from variety of sensors and Internet-of-Things (IoT) inputs to collect real-time information on developing and active emergency situations. Genasys uses this information to create and disseminate alerts, warnings, notifications, and instructions through multiple channels before, during, and after public safety and enterprise threats, critical events, and other crisis situations. The Company operates in two business segments: Hardware and Software and its markets are North and South America, Europe, Middle East and Asia. Key revenue is generated from Hardware.

About MAIA MAIA Biotechnology Inc.

MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of targeted immunotherapies for cancer, with an initial focus on non-small cell lung cancer (NSCLC), which represents the majority of lung cancer cases. Its asset, ateganosine (THIO, also known as 6-thio-dG or 6-thio-deoxyguanosine), is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The treatment approach involves administering THIO followed by the immune checkpoint inhibitor Libtayo (cemiplimab), which is manufactured and commercialized by Regeneron.

Share on Social Networks: